Los Angeles, CA – April 30, 2024 – Mabswitch Inc. was selected as winner from five finalists at a pitch event before Amgen’s (NASDAQ:AMGN)) internal committee that evaluated the strength and novelty of their scientific rationale, subject matter expertise and business plan viability. Mabswitch will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) in Los Angeles as well as additional facility benefits and connections to Amgen’s scientific and business leaders.

The team
From left to right: CTO Stefan Dübel, CEO Yemi Onakunle and Head of Protein Engineering, Kai-Thomas Schneider.

“We are deeply honored and grateful to receive this Golden Ticket from Amgen, a pioneer and true leader in the immunotherapy and cancer therapy space. This remarkable opportunity to access Biolabs LA at the Lundquist Institutes’ state-of-the-art laboratory facilities for a year underscores the promise of our proprietary technologies in transforming antibody-based immunotherapy.  We are enthusiastic about leveraging this invaluable resource to propel our research forward to fulfill our mission of advancing breakthroughs in cancer treatment and making a meaningful impact on patients’ lives.”

Dr. Yemi Onakunle, Founder & CEO

MabSwitch, Inc. (Los Angeles, CA), is a pioneering biotechnology company that utilizes a proprietary universal allosteric-linker and switch module for antibodies (UNASMA™) technology to develop regulatable next-generation antibody-based immunotherapies such as switchable affinity T-Cell Engagers (SaefTE-TM) and switchable affinity CAR (SaefCAR-TM) T-cell therapies that are safer and more effective for the curative treatment of cancer and other devastating chronic diseases of significantly unmet medical need.

Amgen supports life science startups through Golden Ticket awards and affiliated engagement in other biotech innovation hubs, including San Francisco, Boston, Singapore and Toronto.

Categories: News